A detailed history of Lpl Financial LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Lpl Financial LLC holds 18,669 shares of ARVN stock, worth $163,353. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,669
Previous 16,592 12.52%
Holding current value
$163,353
Previous $408,000 12.5%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$17.83 - $28.04 $37,032 - $58,239
2,077 Added 12.52%
18,669 $357,000
Q3 2024

Nov 08, 2024

BUY
$23.66 - $32.73 $42,233 - $58,423
1,785 Added 12.06%
16,592 $408,000
Q2 2024

Aug 07, 2024

SELL
$24.46 - $40.4 $26,392 - $43,591
-1,079 Reduced 6.79%
14,807 $394,000
Q1 2024

May 10, 2024

BUY
$36.38 - $52.31 $95,024 - $136,633
2,612 Added 19.68%
15,886 $655,000
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $188,358 - $561,888
13,274 New
13,274 $546,000
Q2 2022

Aug 12, 2022

SELL
$36.01 - $74.24 $118,544 - $244,398
-3,292 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$60.27 - $81.57 $109,329 - $147,967
-1,814 Reduced 35.53%
3,292 $222,000
Q4 2021

Feb 14, 2022

SELL
$65.85 - $96.21 $8,033 - $11,737
-122 Reduced 2.33%
5,106 $419,000
Q3 2021

Nov 15, 2021

BUY
$73.2 - $107.87 $74,883 - $110,351
1,023 Added 24.33%
5,228 $430,000
Q2 2021

Aug 13, 2021

BUY
$60.45 - $84.26 $254,192 - $354,313
4,205 New
4,205 $324,000
Q1 2021

May 14, 2021

SELL
$58.19 - $91.37 $163,804 - $257,206
-2,815 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$20.19 - $84.93 $56,834 - $239,077
2,815 New
2,815 $239,000

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $466M
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Lpl Financial LLC Portfolio

Follow Lpl Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lpl Financial LLC with notifications on news.